EXEL
Price
$43.66
Change
+$0.57 (+1.32%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
11.91B
46 days until earnings call
ORMP
Price
$2.15
Change
-$0.02 (-0.92%)
Updated
Jun 27, 04:58 PM (EDT)
Capitalization
87.83M
46 days until earnings call
Interact to see
Advertisement

EXEL vs ORMP

Header iconEXEL vs ORMP Comparison
Open Charts EXEL vs ORMPBanner chart's image
Exelixis
Price$43.66
Change+$0.57 (+1.32%)
Volume$61.06K
Capitalization11.91B
Oramed Pharmaceuticals
Price$2.15
Change-$0.02 (-0.92%)
Volume$100
Capitalization87.83M
EXEL vs ORMP Comparison Chart in %
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. ORMP commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongBuy and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (EXEL: $43.67 vs. ORMP: $2.15)
Brand notoriety: EXEL: Notable vs. ORMP: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 96% vs. ORMP: 86%
Market capitalization -- EXEL: $11.91B vs. ORMP: $87.83M
EXEL [@Biotechnology] is valued at $11.91B. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 2 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 2 green, 3 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 1 bullish TA indicator(s).

  • EXEL’s TA Score: 4 bullish, 3 bearish.
  • ORMP’s TA Score: 1 bullish, 8 bearish.
According to our system of comparison, EXEL is a better buy in the short-term than ORMP.

Price Growth

EXEL (@Biotechnology) experienced а +8.17% price change this week, while ORMP (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($11.9B) has a higher market cap than ORMP($87.8M). ORMP (20.91) and EXEL (19.94) have similar P/E ratio . EXEL YTD gains are higher at: 31.141 vs. ORMP (-11.157). EXEL has higher annual earnings (EBITDA): 844M vs. ORMP (-21.53M). EXEL has more cash in the bank: 1.03B vs. ORMP (131M). ORMP has less debt than EXEL: ORMP (301K) vs EXEL (187M). EXEL has higher revenues than ORMP: EXEL (2.3B) vs ORMP (2M).
EXELORMPEXEL / ORMP
Capitalization11.9B87.8M13,554%
EBITDA844M-21.53M-3,921%
Gain YTD31.141-11.157-279%
P/E Ratio19.9420.9195%
Revenue2.3B2M114,950%
Total Cash1.03B131M787%
Total Debt187M301K62,126%
FUNDAMENTALS RATINGS
EXEL vs ORMP: Fundamental Ratings
EXEL
ORMP
OUTLOOK RATING
1..100
6411
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
26100
SMR RATING
1..100
3294
PRICE GROWTH RATING
1..100
4058
P/E GROWTH RATING
1..100
9250
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (58) in the Pharmaceuticals Other industry is in the same range as EXEL (73) in the Biotechnology industry. This means that ORMP’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (26) in the Biotechnology industry is significantly better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew significantly faster than ORMP’s over the last 12 months.

EXEL's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for ORMP (94) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew somewhat faster than ORMP’s over the last 12 months.

EXEL's Price Growth Rating (40) in the Biotechnology industry is in the same range as ORMP (58) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for EXEL (92) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELORMP
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OMI8.870.54
+6.48%
Owens & Minor
VLRS4.670.17
+3.78%
CONTROLADORA VUELA COMPAniA DE AVIACIoN SAB DE CV
ALV113.101.97
+1.77%
Autoliv
WBX0.33N/A
+1.52%
Wallbox NV
OBLG3.10-0.10
-3.12%
Oblong Inc

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.35%
JAZZ - EXEL
35%
Loosely correlated
-0.53%
ALNY - EXEL
34%
Loosely correlated
+1.50%
TECH - EXEL
33%
Poorly correlated
-1.82%
MRSN - EXEL
32%
Poorly correlated
-10.46%
ORMP - EXEL
32%
Poorly correlated
-0.92%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-0.92%
BTAI - ORMP
44%
Loosely correlated
-14.63%
INO - ORMP
44%
Loosely correlated
-6.22%
MBIO - ORMP
44%
Loosely correlated
-0.97%
VERV - ORMP
44%
Loosely correlated
+0.40%
ZNTL - ORMP
43%
Loosely correlated
-6.35%
More